Vorasidenib
Vorasidenib is an oral targeted therapy that inhibits IDH1 and IDH2 enzymes, which are mutated in certain brain tumors. It is specifically approved for the treatment of grade 2 glioma in adults who have a susceptible IDH1 or IDH2 mutation and require additional surgery after initial biopsy or partial resection. This precision medicine approach targets the specific genetic drivers of certain brain tumors.
Vorasidenib is an IDH1/2 inhibitor used to treat grade 2 glioma with IDH mutations in adults requiring additional surgery.
Key facts at a glance
- ATC
- L01XM04
- RxNorm
- 2690647
- Generic
- Vorasidenib
- Class
- atc-l01
- Brands
- Voranigo
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of grade 2 glioma in adults with susceptible IDH1 or IDH2 mutations who require additional surgery following biopsy or partial resection. Diagnosis of IDH mutation status should be confirmed using an FDA-approved companion diagnostic test prior to treatment initiation.
Vorasidenib is a small molecule inhibitor that targets and blocks isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) enzymes. In tumors with IDH mutations, these enzymes produce an oncometabolite (2-hydroxyglutarate) that promotes tumor growth and progression. By inhibiting these mutated enzymes, vorasidenib reduces levels of this oncometabolite and may slow tumor growth.
Common adverse reactions include fatigue, headache, COVID-19 infection, musculoskeletal pain, diarrhea, nausea, and seizure. Hepatotoxicity with elevated liver enzymes may occur and requires regular monitoring. May cause fetal harm; pregnancy testing recommended before starting treatment. Should be taken as directed with or without food; tablets should be swallowed whole without splitting or crushing.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy